Most theranostics sites are operating well below capacity — not because of infrastructure, but because the referral pathways between oncologists, urologists, and your program were never built. We don't optimize scanners. We fill treatment chairs.
The patients exist. The FDA's expanded Pluvicto approval tripled the addressable market to over 90,000 eligible patients in the US alone. The therapy pipeline is accelerating with 30+ agents in mid- to late-stage trials.
But the referral pathways between the oncologists and urologists who manage these patients and the sites equipped to treat them are fragmented, informal, or nonexistent. The result: credentialed sites sitting at half capacity while eligible patients cycle through chemotherapy because their oncologist has no streamlined way to refer.
This isn't a demand problem. It's a revenue recovery problem. Every empty treatment slot is reimbursement you've already invested to earn — and aren't collecting.
You built the shielded room. You secured the license. You hired the AU. You contracted with the radiopharmacy. Those fixed costs don't wait for patients — they accrue whether you treat one patient a week or ten.
The fastest path to ROI isn't more infrastructure. It's more patients. And more patients come from systematically building the referral relationships that feed your program.
You're credentialed for radioligand therapy but treating fewer patients per week than you projected
You're a dedicated theranostics center that needs to reach capacity to justify the build and satisfy investors
You're a general imaging site offering theranostics alongside diagnostic services and want to grow therapy volume
You're losing eligible patients to academic centers or competitors who built referral networks before you did
Your oncology and urology referrals aren't materializing the way your business plan projected
Your CFO or investors are asking when the theranostics investment breaks even — and you don't have a good answer yet
At ~$40K reimbursement per Pluvicto treatment cycle, every empty slot is a quantifiable loss. Here's what the numbers look like at three common underutilization levels.
Figures based on approximate Pluvicto per-cycle reimbursement. Actual revenue varies by payer mix, treatment protocol, and site-specific factors.
We don't do generic healthcare marketing. We combine specialized referral networks, proprietary market intelligence, and clinical education into a revenue recovery system built specifically for theranostics.
We identify and activate the oncologists, urologists, and referring specialists in your market who are actively managing patients eligible for theranostic therapies — and build direct, zero-friction referral relationships between their practices and your site.
We navigate the full spectrum of referring practice structures — from independent physicians to PE-backed specialty groups and hospital-employed networks — each of which requires a different engagement strategy and entry point.
Every engagement starts with data. We build a proprietary picture of your regional opportunity — combining claims-based analysis, provider mapping, and primary market research to quantify exactly how many eligible patients are in your catchment area and where they're being managed.
You'll know the size of your addressable market, which practices control patient flow, what your competitive landscape looks like, and where the highest-conversion referral opportunities sit.
Many referring oncologists and urologists are still unfamiliar with radioligand therapy eligibility criteria, treatment workflows, and referral logistics. Endocrinologists managing thyroid and neuroendocrine cases face similar knowledge gaps around newer theranostic options. We close that gap for your site.
Through physician education programs, clinical content, and CME-eligible events, we position your site as the go-to theranostics partner for referring practices — so referrals come to you first, not your competitor.
A structured engagement designed to systematically build, activate, and optimize the referral pipeline that drives your theranostics program to full capacity utilization.
This isn't a marketing plan. It's a capacity utilization strategy built by someone who has spent 15 years inside the imaging industry and understands how physician referral relationships and treatment economics actually work in practice.
Book a 20-minute discovery call and receive a complimentary, data-driven audit of the revenue opportunity in your market — before you commit to anything.
For imaging sites evaluating or developing advanced imaging and theranostics capabilities, we offer strategic advisory services — helping you navigate the complex decisions around equipment, licensing, and program design so you build right the first time.
Vendor-neutral guidance for imaging centers considering adding PET/CT or optimizing an existing program. 15 years of equipment industry expertise applied to your specific situation.
Strategic guidance for sites evaluating radioligand therapy capabilities — whether you're adding therapy to an existing PET/CT program or designing a dedicated outpatient theranostics center.
20-minute conversation about your site, capacity, and goals. You receive a complimentary Regional Opportunity Audit.
Proprietary analysis of your regional physician landscape, eligible patient volume, and revenue opportunity.
Zero-friction referral pathways, targeted physician outreach, clinical education, and coordinator workflows.
Monthly tracking, capacity analysis, and ongoing optimization to sustain growth and maximize throughput.
We don't care which scanner you use or which isotope you buy — we only care how many patients are in the chair.
15 years in medical imaging means we understand PSMA PET/CT workflows, radioligand therapy eligibility, and how oncologists and urologists actually make referral decisions. We don't need your team to educate us — we educate the referring physicians.
Every engagement starts with proprietary market intelligence — patient volume estimates, physician practice mapping, payer analysis, and competitive positioning. We target the referral sources most likely to convert, based on data, not guesswork.
We don't sell equipment, pharmaceuticals, or therapy services. Our only metric is your capacity utilization. That independence means oncologists and urologists trust us — and that trust transfers directly to your site.
We understand that a single additional Pluvicto treatment cycle represents $40K+ in reimbursement. Our entire methodology is designed around the specific referral dynamics, patient eligibility criteria, and treatment economics of radioligand therapy programs.
After 15 years inside the imaging equipment industry — across major OEMs, service organizations, and clinical operations — I kept seeing the same pattern: sites investing millions in theranostics infrastructure, then watching their suites sit half-empty because no one built the outreach engine.
The consolidators have dedicated business development teams. The academic centers have built-in referral networks. But the independent sites and community programs doing this work? They're left to figure out the hardest part — getting patients in the door — on their own.
I've sat across the table from hundreds of imaging center operators. The ones who succeed aren't the ones with the best scanners — they're the ones who built the referral engine before they built the suite. That's what Summit delivers.
Capacity utilization is our core focus, but theranostics programs don't operate in isolation. When our clients need support beyond referral development — whether it's physics, regulatory, or operational — we connect them with vetted industry partners who meet our standards.
We're building a curated network of specialists across the theranostics ecosystem so our clients always have access to the right expertise at the right time. Our role is to be the connection point — ensuring your program has what it needs to succeed, not just to fill schedules, but to deliver outstanding patient care.
Questions we hear most from site operators and theranostics program leaders evaluating capacity growth.
Every week at partial capacity is revenue you've already invested to earn. Book a 20-minute call and get your complimentary Regional Opportunity Audit — a data-driven assessment of the referral opportunity in your market.
A focused 20-minute conversation about your site, your current capacity utilization, and your growth goals. We'll share what we're seeing in the theranostics referral landscape and give you an honest assessment of the revenue opportunity — including whether our program is the right fit for where you are right now.
Included with every call: Your complimentary Regional Opportunity Audit — proprietary market intelligence on the revenue opportunity in your specific service area. No strings attached.
We respond to all inquiries within 24 hours.
We partner with one theranostics site per defined service area to ensure referral exclusivity. If your market is already taken, we'll let you know.
Thank you. We'll be in touch within 24 hours to schedule your discovery call and begin preparing your Regional Opportunity Audit.